Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

This segment delves into targeting the androgen receptor pathway and conquering treatment resistance for potential breakthroughs in managing advanced prostate cancer

EP: 1.Metastatic Prostate Cancer: Background and Patient Prognosis

EP: 2.Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

EP: 3.Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life

EP: 4.Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis

Now Viewing

EP: 5.Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

EP: 6.Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

EP: 7.Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer

Related Videos

Related Content

Advertisement

December 14th 2022

Study finds only half of patients undergoing 24-hour urine tests receive complete testing

Hannah Clarke

“One of the goals of this study was to look at whether 24-hour urine testing in the VA population included all the important components of 24-hour urine panel testing,” says Ryan Hsi, MD, FACS.

November 2nd 2022

Dr. Chew and Dr. Bhojani highlight their findings on sepsis rates post ureteroscopy

Urology Times staff

Naeem Bhojani, MD, and Ben H. Chew, MD, MSc, FRCSC, discuss the burden of sepsis post-URS to both the healthcare system and patients.

October 19th 2022

Study finds inadequate patient education for scheduled urologic procedures

Hannah Clarke

Researchers at Albert Einstein College of Medicine found patients benefited from a pre-procedural interview to educate them about the risks, benefits, and alternatives to urologic treatments they were scheduled to receive.

February 2nd 2021

First European patient treated for urethral stricture with novel drug-coated balloon catheter

Jason M. Broderick

The Optilume drug-coated balloon catheter system was approved in the EU in September 2020 for the treatment of patients with urethral stricture.

November 24th 2020

FDA approves lumasiran as first drug for primary hyperoxaluria type 1

Jason M. Broderick

The treatment is approved for both adult and pediatric patients.

Related Content

Advertisement

December 14th 2022

Study finds only half of patients undergoing 24-hour urine tests receive complete testing

Hannah Clarke

“One of the goals of this study was to look at whether 24-hour urine testing in the VA population included all the important components of 24-hour urine panel testing,” says Ryan Hsi, MD, FACS.

November 2nd 2022

Dr. Chew and Dr. Bhojani highlight their findings on sepsis rates post ureteroscopy

Urology Times staff

Naeem Bhojani, MD, and Ben H. Chew, MD, MSc, FRCSC, discuss the burden of sepsis post-URS to both the healthcare system and patients.

October 19th 2022

Study finds inadequate patient education for scheduled urologic procedures

Hannah Clarke

Researchers at Albert Einstein College of Medicine found patients benefited from a pre-procedural interview to educate them about the risks, benefits, and alternatives to urologic treatments they were scheduled to receive.

February 2nd 2021

First European patient treated for urethral stricture with novel drug-coated balloon catheter

Jason M. Broderick

The Optilume drug-coated balloon catheter system was approved in the EU in September 2020 for the treatment of patients with urethral stricture.

November 24th 2020

FDA approves lumasiran as first drug for primary hyperoxaluria type 1

Jason M. Broderick

The treatment is approved for both adult and pediatric patients.